Simvastatin increases the in vivo activity of the first-line tuberculosis regimen

BACKGROUND: The need to develop new, improved treatments for tuberculosis (TB) remains urgent, and the repurposing of existing drugs represents a possible shortcut to market. Recently, there has been significant interest in host-directed adjuvant therapy to enhance bacillary killing. HMG-CoA reducta...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Skerry, Ciaran, Pinn, Michael L., Bruiners, Natalie, Pine, Richard, Gennaro, Maria L., Karakousis, Petros C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2014
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184365/
https://ncbi.nlm.nih.gov/pubmed/24855121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dku166
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky